NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.90
+10.95%Oct 29, 2026, 11:46 UTC
NovoCure reported third-quarter 2026 revenue of $193.4 million, up 16% year over year, and a net loss of $10.4 million, or $0.09 per diluted share.
Source:Oct 28, 2026, 11:00 UTC
NovoCure Ltd announced that it entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy with chemotherapy and VS-7375 for locally advanced pancreatic cancer.
Source:Sep 9, 2026, 11:05 UTC
Timothy Scannell retired as a Director of NovoCure Ltd, effective September 2, 2026.
Sep 1, 2026, 11:54 UTC
Oncology company Novocure disclosed a cybersecurity incident involving unauthorized access to its information systems in mid-August, which exposed internal records of more than 1,400 U.S. patients.
Source:Jul 23, 2026, 11:00 UTC
Novocure reported financial results for the second quarter ended June 30, 2026, with record net revenues and active patients on therapy.
Source:Jun 30, 2026, 11:00 UTC
Novocure received CE Mark for Optune Pax for the treatment of locally advanced pancreatic cancer.
Source:Jun 18, 2026, 11:08 UTC
Novocure's cancer treatment for newly diagnosed brain tumors failed to meet the main goal of a late-stage study.
Source:Jun 5, 2026, 00:00 UTC
NovoCure Ltd elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, and Frank Leonard as directors, effective June 3, 2026.